Combo of old drugs offers new hope in obesity fight
A Food and Drug Administration panel on Tuesday (Dec.7,2010) recommended that the agency approve Orexigen Therapeutics Inc.'s weight loss drug Contrave, making it the first in group of competitors to get a positive nod from experts.
The panel of experts voted 13 to 7 for Contrave's approval, and 11 to 8, with an abstention, that additional studies be conducted on heart risks. Experts had voiced safety concerns on the drug, but determined the benefits outweigh the risks.
The move marks an about–face on weight loss drugs after the agency in October rejected Arena Pharmaceuticals Inc.'s lorcaserin and Vivus Inc.'s Qnexa because of safety concerns.
The FDA is not required to follow the
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment